炎症性肠病患者两种Fendrix乙型肝炎疫苗接种方案比较
这项回顾性队列研究比较了炎症性肠病患者接受含初始双倍剂量Fendrix的改良接种方案与标准方案的血清学应答,两组血清保护率分别为86.2%和88.9%,约三分之一患者仅接种一剂双倍剂量疫苗后即获得血清保护。作者认为,对于短期HBV感染风险高、需要快速保护性应答的炎症性肠病患者,可考虑双倍剂量。
要点
- 改良方案组血清保护率为86.2%,标准方案组为88.9%。
- 约三分之一患者仅接种一剂双倍剂量Fendrix后即获得血清保护。
- 作者认为短期HBV感染风险高的IBD患者可考虑双倍剂量以快速获得保护。
核心结论
- 改良方案组血清保护率为86.2%,标准方案组为88.9%。
- 约三分之一患者仅接种一剂双倍剂量疫苗后即获得血清保护。
- 作者认为,对于短期HBV感染风险高、需要快速保护性应答的炎症性肠病患者,可考虑双倍剂量。
研究设计与样本
- 回顾性队列研究,纳入炎症性肠病患者,比较含初始双倍剂量Fendrix的改良接种方案与标准方案的血清学应答。
主要发现
- 改良方案组血清保护率为86.2%,标准方案组为88.9%。
- 约三分之一患者仅接种一剂双倍剂量疫苗后即获得血清保护。
临床怎么用
- 作者认为,对于短期HBV感染风险高、需要快速保护性应答的炎症性肠病患者,可考虑双倍剂量。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic immunosuppressive therapy (IS) renders patients with inflammatory bowel disease (IBD) vulnerable to fulminant hepatitis B virus (HBV) infection. Seroprotection against HBV through a full vaccination scheme is preferably obtained before IS is initiated, but often conflicts with the clinical need to initiate therapy rapidly. Consequently, the vast majority of patients will use IS during booster vaccinations. In this retrospective cohort study, we examined the serological response after a modified vaccination schedule which includes an initial double dose of Fendrix in patients with IBD and compared the results with the serological responses of patients with IBD who received the standard schedule. Seroprotection rates were 86.2 % and 88.9 % in the modified and standard schedule groups respectively. One-third of patients obtained seroprotection after only one double dose vaccine. A double dose may be considered in patients with IBD at high short-term risk of HBV infection when a rapid protective response is warranted.
引用
- Kuiper VP, van der Plas P, Hoogerwerf MA, et al. A comparison of two Fendrix hepatitis B vaccination schedules in patients with inflammatory bowel disease. Vaccine. 2022. PMID: 36154758. doi:10.1016/j.vaccine.2022.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。